Frost & Sullivan Recognizes Immtech International with 2004 Customer Value Enhancement Award for Global Health Initiatives.

BOSTON -- Frost & Sullivan has presented Immtech International with the prestigious 2004 Customer Value Enhancement Award for Global Health Initiatives, acknowledging Immtech's commitment to create superior value for its customers by constantly striving to bring more efficacious treatments to market.

"Immtech's tireless efforts to surmount the rigorous international clinical development pathway have been instrumental in making this possible," says Frost & Sullivan research analyst Curt A. Herberts III. "Using highly innovative business development strategies, Immtech has been able to hasten both licensing and product development, thereby increasing the speed and productivity of drug development, in addition to alleviating the suffering of disease-ridden populations across the world."

The company's strong focus on oral therapeutics to treat infectious diseases is expected to bring relief to developing nations by increasing the number of potential treatments to cure these debilitating epidemics. Much of its drug development efforts are aimed at identifying novel therapeutics for infectious diseases that either lack current treatments or do not respond to older therapies because of minimized efficacy.

Immtech's most promising compound, DB289, is currently in development for the treatment of malaria, pneumocystis carinii pneumonia (PCP), and African sleeping sickness.

Given that malaria is the second-deadliest infectious disease in the world, accounting for one million deaths of children every year in developing countries, there is an urgent need for effective therapies to cure the epidemic. Immtech's DB289, which is currently undergoing a Phase IIa clinical trial, is targeted toward the most lethal forms of malaria virus - Plasmodium vivax and Plasmodium falciparum.

Initial clinical and preclinical data demonstrated encouraging results, revealing that DB289 reached blood concentration levels that are likely to be able to treat malaria in human beings. Further research at the Swiss Tropic Institute showed that DB289 demonstrated positive activity against several forms of this disease including known drug-resistant strains.

With its innovative oral formulation and ease of administration, Immtech has had great success in securing substantial funding to push this drug through the international regulatory clinic. Organizations such as Medicines for Malaria Venture and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have pledged their financial support for Immtech's development of new oral drugs for malaria.

Immtech has simultaneously been pursuing DB289 in Phase IIb development for PCP, a type of fungal infection of the lungs associated with AIDS infection. Early clinical trials revealed that more than 90 percent of patients exhibited improved lung function following treatment. Notably, DB289 is the only compound in development, at present, for this particular disease.

Additionally, a Phase III study with DB289 is in progress for African sleeping disease otherwise known as Trypanosomiasis. In a Phase IIa study conducted in 2002, it was determined that this novel compound was highly effective in treating Trypanosomiasis, with 95 percent of the participants remaining parasite-free up to three to six months after treatment. Expected positive results from the Phase III trials will help Immtech obtain regulatory approval for this therapy and make a critical difference in many African nations.

"Immtech's selective focus on promising compounds in late-stage development and continued devotion toward aggressive product initiatives will help it to bring great value and superior therapies through the regulatory pathway, which in the end will positively impact the health of people around the world," concludes Herberts.

Held in Boston, the Frost & Sullivan banquet will honor world-class companies for outstanding performance and achievements in customer care. An annual event, the banquet recognizes the quality and merit of distinguished individuals and companies.

About Immtech International, Inc.

Immtech International, Inc. is a pharmaceutical company focused on commercializing a new class of oral therapeutics to treat infectious diseases. Global annual sales in 2003 for anti-infective drugs are estimated to be $46 billion. The company is committed to developing oral drugs to treat diseases for which there is no cure or to replace existing drugs that have become less effective. Immtech is developing oral drugs to treat infectious diseases such as pneumonia, fungal infections ($4 billion annual sales), malaria (affecting 2 billion people and causing 2 million deaths annually), tuberculosis (affecting 2 billion people and causing 2 million deaths annually), diabetes (affecting 170 million people), hepatitis ($2 billion annual sales), and tropical diseases such as African sleeping sickness (affecting 60 million people) and Leishmania (prevalent in 80 countries). Immtech is succeeding with its multi-pronged drug development program because of its time/cost-efficient business model that enables it to address the enormous demands for a new generation of oral anti-infectives. Immtech has worldwide, exclusive rights to commercialize a dicationic pharmaceutical platform from which a pipeline of products may be developed to target large global markets.

About Frost & Sullivan

Founded in 1961, Frost & Sullivan is recognized as a global leader in growth consulting. Frost & Sullivan Awards are presented to companies that demonstrate excellence in their industry, commending the diligence, commitment, and innovative business strategies required to advance in the global marketplace. Frost & Sullivan rigorously analyzes specific criteria to determine award recipients in a variety of market industries and landscapes. For further information, visit www.frost.com.